Gem Pharmatech Lands $23 Million In Series A Financing.

Gem Pharmatech just received around 23 million dollars in Series A financing, this round of financing was led by CDH Investment and Sinopharm Group. The funds will be used for developing animal models, building new production center and overseas expansion to support global life science research and clinical development of new drugs.

Gem Pharmatech was founded in 2017, it’s a technology company specializing in the development, application and supply of genetically engineered mouse models. In the past 2 years, Gem Pharmatech established the “Human Tumor Immune Resource Library”, Providing core tools for the development of macromolecular drugs for tumor immunity.

Gem Pharmatech is committed to building the world's largest library of mouse strains, and now has more than 8,000 genetically edited mouse strains, including nearly 100 popular tumor-immune mouse models. The company has more than 750 customers, covering most pharmaceutical companies, CROs and scientific research institutions in China.

Model animals are experimental animals used to replace human body research, and mice are considered to be the most important model of animals. Gem Pharmatech has developed the world's leading mouse model building system, and can also help customers with mouse model selection and design.

CDH Investments is an international alternative asset fund manager with more than 2 billion dollars of committed capital under management.

Sinopharm is the largest Chinese medical and healthcare group directly managed by State-owned Assets Supervision and Administration Commission of the State Council (SASAC).